Company expects early 2026 rollout in EEA; physician portal combines Lumee™ oxygen monitoring with NVIDIA NeMo to deliver AI-driven clinical workflows BERKELEY, Calif, Sept. 11, 2025 (GLOBE NEWSWIRE) -- Profusa, Inc. (“Profusa” or the “Company”) (Nasdaq: PFSA), a commercial stage digital health company pioneering a next-generation technology platform enabling the continuous monitoring of an individual’s biochemistry, announces the adoption of NVIDIA technology to power an AI-driven insight p

NEW YORK, Sept. 11, 2025 (GLOBE NEWSWIRE) -- SELLAS Life Sciences Group, Inc. (NASDAQ: SLS) (“SELLAS” or the “Company”), a late-stage clinical biopharmaceutical company focused on the development of novel therapies for a broad range of cancer indications, today announced the immediate exercise of warrants, previously issued in January 2025, to purchase up to 19,685,040 shares of its common stock for gross cash proceeds of approximately $23.6 million. In consideration for the immediate exerc

MORRISTOWN, N.J., Sept. 11, 2025 (GLOBE NEWSWIRE) -- Intercept Pharmaceuticals, Inc., a wholly owned biopharmaceutical subsidiary of Alfasigma S.p.A., today announced its decision to voluntarily withdraw OCALIVA® (obeticholic acid) from the US market for the treatment of primary biliary cholangitis (PBC), a rare, progressive liver disease. This decision follows a request from the US Food and Drug Administration (FDA). In addition, FDA has placed a clinical hold on all Intercept clinical trials

Presentations collectively highlight pilavapadin’s potential to improve pain management care for patients with diabetic peripheral neuropathic pain (DPNP) Breadth of the data across Phase 2 program to be discussed at Arrowhead’s 19th Annual Pain Summit THE WOODLANDS, Texas, Sept. 11, 2025 (GLOBE NEWSWIRE) -- Lexicon Pharmaceuticals, Inc. (Nasdaq: LXRX) today announced the presentation of clinical data for its investigational, AAK1-inhibitor, pilavapadin, for the treatment of diabetic periphe

DRAPER, Utah, Sept. 11, 2025 /PRNewswire/ -- Nexus Spine is excited to share pilot study results of a comparative radiographic assessment of ACDF outcomes in a series of patients who were selected for common risk factors of subsidence, instability, and delayed bone growth. Specifically, the patients were over 66 years of age, had poor bone quality, and/or required cervical fusion surgery at three or more contiguous levels. Each patient received a Nexus Spine Tranquil ® cervical interbody cage at

SHANGHAI, Sept. 11, 2025 /PRNewswire/ -- YolTech Therapeutics, a clinical-stage biotech company pioneering in vivo genome editing therapies, today announced the closing of its approximately $45 million Series B financing led by the AstraZeneca-CICC healthcare investment fund. The proceeds will support the advancement of YolTech's clinical programs and global strategic execution. Dr. Yuxuan Wu, Founder and CEO of YolTech, "This financing marks an important milestone as we continue advancing our p

SAN DIEGO, Sept. 11, 2025 /PRNewswire/ -- PhenoVista Biosciences and Carolina Molecular announce a partnership to combine their complementary CRO service capabilities to expand client access to broader multi-omic data. PhenoVista is a premier provider of cell-based assay services, specializing in high-content imaging and analysis, including downstream machine learning and subsequent quantitative biology. The partnership with Carolina Molecular allows shared clients to complement the functional a

GIP acceptance builds on Neu's FDA clearance for Parkinson's tremor measurement and major U.S. health system pilots with entry into America's largest medical innovation hub LONDON, Sept. 11, 2025 /PRNewswire/ -- Neu Health, a precision neurology platform for Parkinson's and dementia, today announced its selection for the Global Incubator Programme (GIP): USA HealthTech - Medical Devices. The six‑month programme is delivered by Innovate UK in partnership with Texas Medical Center Innovation (TMCi

Latest Evidence Confirms Excellent Outcomes for Patients with Brain Metastases that have Returned After Prior Radiation TEMPE, Ariz., Sept. 11, 2025 /PRNewswire/ -- GT Medical Technologies, a medical device company dedicated to improving the lives of patients with brain tumors, today announced the publication of new clinical data in the Journal of Neuro-Oncology. The study, titled "Cesium-131 collagen tile brachytherapy for salvage and recurrent intracranial metastases," was led by investigators

Expands Amneal’s Affordable Medicines portfolio and broadens patient accessBRIDGEWATER, N.J, Sept. 11, 2025 (GLOBE NEWSWIRE) -- Amneal Pharmaceuticals, Inc. (“Amneal” or the “Company”) today announced the U.S. Food and Drug Administration (FDA) approval of Amneal’s sodium oxybate oral solution 500 mg/mL Abbreviated New Drug Application (ANDA) which references Jazz Pharmaceuticals’ Xyrem®. Amneal had previously been distributing an authorized generic of sodium oxybate oral solution in limited q